N-(4-hydroxyphenyl)retinamide prevents development of T-lymphomas in AKR/J mice.
N-(4-Hydroxyphenyl)retinamide (4-HPR), a synthetic retinoic acid derivative, has chemopreventive effects on several types of cancer. We recently showed that 4-HPR is a potent inducer of apoptosis in malignant, but not normal, T-lymphoid cells in vitro. To test 4-HPR's effect in vivo, we used the virus-induced T-lymphoma in AKR/J mice as a model system. The AKR/J mice were fed 4-HPR at 0, 1 or 2 mmole/kg diet, and the animals were monitored as to tumor development, plasma level of 4-HPR, body weight, appetite, and general health. Our results show that in a 19-week period, 4-HPR prevented T-lymphoma development by 40% and 50% of animals fed 1 and 2 mmole 4-HPR/ kg diet, respectively. In the plasma, 4-HPR reached micromolar levels without causing any observable deleterious side-effects. Thus, 4-HPR is potentially useful in chemoprevention of lymphoid cancers.
Chan
L N
LN
Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch at Galveston 77555, USA.
Zhang
S
S
Cloyd
M
M
Chan
T S
TS
D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D005260:Female; D017313:Fenretinide / Q000097:blood / Q000627:therapeutic use*; D008198:Lymph Nodes / Q000187:drug effects; D016399:Lymphoma, T-Cell / Q000517:prevention & control*; D051379:Mice; D008806:Mice, Inbred AKR; D013154:Spleen / Q000187:drug effects; D013950:Thymus Gland / Q000187:drug effects
D016588:Anticarcinogenic Agents; D017313:Fenretinide